Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM).

Shih, Kuan-Hui; Spigel, David R.; Burris, Howard A.; Brown, R. H.; Shepard, Gregg; Hainsworth, John D.

doi:10.1200/jco.2010.28.15_suppl.2075

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CR was observed in 2% of the patients, partial response (PR) in 30%, SD in 52%, 11% were unevaluable, and 5% were too early to assess. This novel first-line therapy for GBM incorporating bevacizumab and everolimus was well tolerated by most patients and seems to hold promise worth further evaluation [127].…”

Section: Rapalog Clinical Activity In Common Tumor Typesmentioning

confidence: 97%

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

et al. 2011

View full text Add to dashboard Cite

The phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway is vital for cell metabolism, growth, and proliferation. mTOR is frequently upregulated in many tumor types and hence has become an important target in cancer treatment. Sirolimus and its derivatives (rapalogs) interact with the intracellular receptor FK506 binding protein 12 (FKBP12), forming a complex with high affinity for mTOR and thus disrupting its activity. Rapalogs are being evaluated extensively in cancer patients with different formulations and schedules. Significant clinical activity has led to their approval for the treatment of kidney cancer, mantle cell lymphoma, and subependymal giant cell astrocytoma; however, despite increasing knowledge about cancer cell biology, their activity in other malignancies is unclear. Further research is needed to identify optimal dosage, administration and targeted combination as well as the subset of patients likely to respond to mTOR/PI3K inhibition. This review focuses on a discussion of the pathway, its implications in cancer biology and results of clinical trials of rapalogs alone or in combination, organizing them by common malignancy type.

show abstract

Section: Rapalog Clinical Activity In Common Tumor Typesmentioning

confidence: 97%

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

et al. 2011

View full text Add to dashboard Cite

show abstract

Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis

Habibi,

Shad,

Mirjnani

et al. 2024

Neurosurg Rev

View full text Add to dashboard Cite

Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials

Khasraw

Ameratunga

Grommes

2014

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Bevacizumab has been shown to be safe and tolerable in HGG. In the recurrent disease setting, bevacizumab might offer clinical benefits and is currently approved as a single agent for this indication. Although clinical trials demonstrate a prolonged progression-free survival (PFS) in bevacizumab-treated HGG, a benefit on overall survival has not been demonstrated. Research so far shows that bevacizumab appears to prolong PFS in newly diagnosed glioblastoma. Available data do not demonstrate a survival benefit in newly diagnosed patients. In the recurrent setting, there is no adequately powered randomized clinical trial to address whether there is a PFS or survival benefit with bevacizumab. Bevacizumab has also been introduced into other settings in neuro-oncology, including concurrent administration with re-irradiation for recurrent HGG.

show abstract

Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM).

Cited by 4 publications

References 0 publications

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis

Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials

Contact Info

Product

Resources

About